Morgan Stanley has executed a second sale in four months for Elan, the Irish pharmaceuticals group run by a 21-year Merrill Lynch veteran.
Elan retained Morgan Stanley to advise it on its primary care business to US rival King Pharmaceuticals for up to $950m (€874m).